biopharma-reporter2h
SEKISUI Diagnostics completes £15.7M expansion to boost biopharma manufacturing capacity
New cGMP fermentation facility in the UK set to meet growing demand for drug substance production, supporting biopharma ...
biopharma-reporter1h
Promising early Parkinson’s immunotherapy results for AC Immune
The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.
biopharma-reporter6h
Alentis raises $181 million to advance ADCs to the clinic
The Series D financing will support the clinical development of two ADCs.
biopharma-reporter2d
FDA removes clinical hold on Novavax’s COVID-19-influenza combo vaccine
The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.
biopharma-reporter2d
AbbVie’s schizophrenia candidate fails in two phase 2 trials
Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...
biopharma-reporter9d
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi
The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis. The European Medicines Agency (EMA) has accepted Alvotech and Advanz Pharma ...
biopharma-reporter9d
Synaffix and BigHat Biosciences collaborate to develop AI-designed ADC
BigHat will have access to the clinical-stage ADC platform technology designed by Lonza’s Synaffix. The Dutch biotech Synaffix and the Swiss company BigHat Biosciences announced yesterday that they ...